IG7 Stock Overview
Develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Memphasys Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.005 |
| 52 Week High | AU$0.0065 |
| 52 Week Low | AU$0.0005 |
| Beta | 0.88 |
| 1 Month Change | 0% |
| 3 Month Change | 66.67% |
| 1 Year Change | 150.00% |
| 3 Year Change | -87.80% |
| 5 Year Change | -86.11% |
| Change since IPO | -50.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| IG7 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 25.0% | -1.7% | 2.1% |
| 1Y | 150.0% | -2.2% | 16.5% |
Return vs Industry: IG7 exceeded the German Life Sciences industry which returned 0% over the past year.
Return vs Market: IG7 exceeded the German Market which returned 16.7% over the past year.
Price Volatility
| IG7 volatility | |
|---|---|
| IG7 Average Weekly Movement | 22.8% |
| Life Sciences Industry Average Movement | 6.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: IG7's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IG7's weekly volatility has decreased from 82% to 23% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | n/a | David Ali | www.memphasys.com |
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company primarily develops Felix, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, a rapid oxidative stress assay; and AI-Port.
Memphasys Limited Fundamentals Summary
| IG7 fundamental statistics | |
|---|---|
| Market cap | €8.57m |
| Earnings (TTM) | -€2.69m |
| Revenue (TTM) | €658.92k |
13.0x
P/S Ratio-3.2x
P/E RatioIs IG7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IG7 income statement (TTM) | |
|---|---|
| Revenue | AU$1.09m |
| Cost of Revenue | AU$115.46k |
| Gross Profit | AU$974.38k |
| Other Expenses | AU$5.42m |
| Earnings | -AU$4.44m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0025 |
| Gross Margin | 89.41% |
| Net Profit Margin | -407.58% |
| Debt/Equity Ratio | 64.5% |
How did IG7 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/12 02:11 |
| End of Day Share Price | 2025/02/12 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Memphasys Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.